Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.

•More participants experienced relapse (50/259; 76%) vs reinfection (198/259; 19%).•The proportion of relapses was higher for RT 027 vs all other RTs (84.5% vs 74.1%).•A reduction in relapse incidence was seen in participants receiving bezlotoxumab.